At the end of the LNCaP experiment, that is, 56 days, GR levels in EVs in COMBO group were low compared with vehicle control group, despite tumor regrowth from COMBO treatment (Fig. 5C), suggesting that resistance to mifepristone is GR-independent. This evidence concerns the gene NR3C1 and neoplasm.